RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to sell shares; the loss of the value of investment; and dilution of shareholding. When you invest any loss in value will not be covered by the the Financial Services Compensation Scheme. Please read FULL risk warning.
Real-time medical diagnostics, improving current cancer screening programmes.
Investment closes only once the total pledged amount passes the minimum of £250,000
This Pledge is not a commitment. You will be asked to confirm in the next section.
Zilico Limited has developed an innovative and patented cancer diagnostic device technology that will improve and extend current cancer screening programmes by providing accurate and objective results real-time.
The Company’s device examines the electrical impedance properties of tissues through electrical resistance analysis and measurement. Different organs have characteristic electrical impedances, and research has shown that it is possible to predict the impedance of different tissues once you know enough about their structure, resulting in knowledge of the impedance spectrum characteristic to a particular tissue. The Company’s technology provides an objective method to differentiate between normal, precancerous, and cancerous cells. This provides a real-time diagnosis that removes subjectivity and potentially avoids the need for a biopsy.
The initial focus of the Company is cervical cancer and oral cancer with future diagnostic activity planned to apply the same approach to oesophageal, anal, vaginal and vulval cancers amongst others. Zilico’s solution is objective whereas other components of the current cervical cancer diagnostic pathway (cytology and colposcopy) are largely subjective and incapable of scientific assessment of performance.
Since the Company’s founding, Zilico has focused upon the development of a research-based instrument into a device appropriate for commercial manufacture and routine use by medical practitioners in the execution of colposcopy (i.e. the medical diagnostic procedure to examine an illuminated, magnified view of the cervix and the tissues of the vagina and vulva). The device, called ZedScan, consists of a handheld device and a docking station, together with a single-use EIS sensor that is required for each patient tested. The two EIS products identified by the Company are the ZedScan for the referral market and the APX200 for the screening market.
"Zilico fits into our overall theme of systems that introduce efficiencies into overburdened global healthcare systems. Its product fits neatly into existing care pathways and it influences how cancer diagnosis impacts patients' lives and, importantly, introduces significant cost savings into hospitals." - DR SAVVAS NEOPHYTOU, HEAD OF LIFE SCIENCES
Important Note: Responses to Q&A come directly from the Management Team and have not been authorised as part of an approved financial promotion. Click here for more information.